Table 1.
Characteristics of a cohort of 105,786 older (≥65 years of age) adults with type 2 diabetes. Kaiser Permanente Northern California Diabetes and Aging Study 2015 Cohort.
| Age groups, % | |
| 65-69 years | 31.1 |
| 70-74 years | 26.4 |
| 75-79 years | 19.6 |
| >=80 years | 22.9 |
| Duration of diabetes, % | |
| <10 years | 45.2 |
| ≥10 years | 54.8 |
| Male sex, % | 51.0 |
| Race/ethnicity, % | |
| Non-Hispanic White | 51.1 |
| Non-Hispanic Black | 8.9 |
| Hispanic | 13.8 |
| East Asian | 8.5 |
| South Asian | 1.5 |
| Filipino | 8.3 |
| Other Asian | 1.6 |
| Pacific Islander | 0.4 |
| Other/Missing | 0.4 |
| Mixed | 4.9 |
| Native American | 0.6 |
| Systolic blood pressure | |
| <130 mm Hg | 48.6 |
| ≥130 mmg Hg | 51.2 |
| Missing | 0.2 |
| LDL cholesterol | |
| <100 mg/dl | 77.9 |
| ≥100 mg/dl | 18.2 |
| Missing | 3.9 |
| A1C categories, % | |
| ≤5.9 | 8.1 |
| 6.0-6.9 | 41.4 |
| 7.0-7.9 | 33.6 |
| 8.0-8.9 | 10.1 |
| 9.0-9.9 | 3.8 |
| ≥10 | 3.0 |
| Estimated GlomerularFiltration Rate 23 , % | |
| ≥90 no albuminuria | 7.2 |
| ≥90 with albuminuria | 2.5 |
| 60-89 | 51.1 |
| 45-59 | 22.2 |
| 30-44 | 12.0 |
| 15-29 | 3.5 |
| <15 or dialysis | 1.2 |
| Missing | 0.4 |
| Baseline comorbid conditions, % | |
| Arthritis | 45.5 |
| Atrial fibrillation | 14.5 |
| Cancer | 12.3 |
| Congestive heart failure | 14.8 |
| Coronary artery disease | 18.2 |
| Dementia | 4.5 |
| Depression | 29.8 |
| Emphysema/Chronic obstructive pulmonary disease | 26.2 |
| End-stage renal disease | 2.1 |
| Falls | 22.3 |
| Foot ulcer | 8.0 |
| Hypertension | 91.1 |
| Liver disease | 15.9 |
| Lower extremity amputation | 1.0 |
| Obesity | 44.2 |
| Peripheral vascular disease | 17.4 |
| Stroke | 4.9 |
| Thyroid disease | 20.3 |
| Urinary incontinence | 12.3 |
| Medications (within past 6 months), % | |
| Taking no diabetes medications | 26.1 |
| Insulin | 23.1 |
| Sulfonylurea | 38.5 |
| Metformin | 50.4 |
| Thiazolidinedione | 2.8 |
| Acarbose | 0.2 |
| Repaglinide | 0.1 |
| ≥2 glucose lowering drugs | 33.7 |
| ≥3 glucose lowering drugs | 7.6 |
| Insulin and oral therapy | 14.4 |
| Statin | 80.7 |
| Other lipid lowering agent | 5.3 |
| ACE inhibitor | 47.2 |
| Other anti-hypertensive | 77.9 |